Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Stopped Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim

Conditions

• NSCLC

Interventions

• DRUG: intercalation therapy using pemetrexed, cisplatin and erlotinib
• DRUG: Vinorelbine, cisplatin

Sponsor

Yonsei University